Literature DB >> 31378586

Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma.

Yuval Freifeld1, Rashed Ghandour1, Nirmish Singla1, Solomon Woldu1, Timothy Clinton1, Rohan Kulangara2, Aditya Bagrodia1, Surena F Matin3, Firas G Petros3, Jay D Raman4, Haley Robyak4, Jingsheng Yan5, Hong Zhu6, Leonid Rapoport7, Yair Lotan1, Vitaly Margulis8.   

Abstract

PURPOSE: To identify preoperative risk factors for disease recurrence, following radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), and to create a predictive nomogram.
MATERIALS AND METHODS: Based on a multicenter database, we identified patients who underwent RNU due to high grade UTUC. Urothelial carcinoma of the bladder or contralateral UTUC was not considered as recurrence. Cox regression model was used to determine the effect of different preoperative variables as predictors of recurrence.
RESULTS: Two hundred and forty-five patients were included in the analysis. The 2 and 5 years recurrence rates were 16.3% and 19.2%, respectively. Factors associated with recurrence on univariable analysis were sessile architecture hazard ratio (HR) 3.16 (95% CI, 1.38-7.26, P = 0.006), ≥cT3 disease HR 2.30 (95% CI, 1.12-4.72, P= 0.023), age >65 HR 2.02 (95% CI, 1.00-4.05, P= 0.048), Eastern Cooperative Group > 0 HR 1.98 (95% CI, 1.09-3.57, P= 0.023), hydronephrosis HR 1.93 (95% CI, 1.04-3.57, P= 0.035). Higher hemoglobin levels HR 0.81 (95% CI, 0.69-0.96, P= 0.013) and preoperative estimated glomerular filtration rate ≥ 50 HR 0.48 (95% CI, 0.25-0.92, P = 0.028) were associated with lower probability for recurrence. Multivariable analysis identified sessile architecture as the only independent predictor of recurrence HR 2.52 (95% CI, 1.09-5.86, P= 0.0308). C-index of 0.71 was calculated for a predictive model including all variables in the multivariable analysis, indicating good predictive accuracy. A nomogram predicting 2 and 5 year recurrence free probability was developed accordingly.
CONCLUSIONS: Based on a multicenter database, we developed a nomogram with good predictive accuracy for recurrence following RNU. This may serve as an aid in decision-making regarding the use of neoadjuvant chemotherapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Metastasis; Nephroureterectomy; Nomogram; Recurrence; UTUC; Upper tract urothelial carcinoma

Year:  2019        PMID: 31378586     DOI: 10.1016/j.urolonc.2019.06.009

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  4 in total

1.  Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.

Authors:  Omar Alhalabi; Matthew T Campbell; Lianchun Xiao; Ana C Adriazola; Nathaniel R Wilson; Arlene O Siefker-Radtke; Paul G Corn; Amado Zurita; Eric Jonasch; Jianjun Gao; Mehrad Adibi; Ashish M Kamat; Neema Navai; Louis L Pisters; Colin Dinney; Surena F Matin; Amishi Y Shah
Journal:  BJUI Compass       Date:  2021-10-11

Review 2.  Optimal Management of Upper Tract Urothelial Carcinoma: Current Perspectives.

Authors:  Jeffrey J Leow; Zhenbang Liu; Teck Wei Tan; Yee Mun Lee; Eu Kiang Yeo; Yew-Lam Chong
Journal:  Onco Targets Ther       Date:  2020-01-06       Impact factor: 4.147

3.  Prognostic Value of Preoperative Hydronephrosis in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urinary Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Tao Ye; Xiaoqi Yang; Peng Lv; Haoran Liu; Zhangqun Ye
Journal:  Front Oncol       Date:  2020-12-11       Impact factor: 6.244

4.  Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics.

Authors:  Frederik König; Nico C Grossmann; Francesco Soria; David D'Andrea; Tristan Juvet; Aaron Potretzke; Hooman Djaladat; Alireza Ghoreifi; Eiji Kikuchi; Nozomi Hayakawa; Andrea Mari; Zine-Eddine Khene; Kazutoshi Fujita; Jay D Raman; Alberto Breda; Matteo Fontana; John P Sfakianos; John L Pfail; Ekaterina Laukhtina; Pawel Rajwa; Maximilian Pallauf; Giovanni E Cacciamani; Thomas van Doeveren; Joost L Boormans; Alessandro Antonelli; Marcus Jamil; Firas Abdollah; Jeffrey Budzyn; Guillaume Ploussard; Axel Heidenreich; Siamak Daneshmand; Stephen A Boorjian; Morgan Rouprêt; Michael Rink; Shahrokh F Shariat; Benjamin Pradere
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.